Anzeige
Mehr »
Login
Mittwoch, 19.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Spektakuläre News bei dieser Aktie - ist das ist die Chance des Jahres?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KBZ1 | ISIN: SE0003491562 | Ticker-Symbol: 16E
Frankfurt
18.03.25
09:16 Uhr
0,002 Euro
+0,000
+33,33 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
EPISURF MEDICAL AB Chart 1 Jahr
5-Tage-Chart
EPISURF MEDICAL AB 5-Tage-Chart
GlobeNewswire (Europe)
37 Leser
Artikel bewerten:
(0)

Episurf Medical AB: CFO Veronica Wallin leaves Episurf Medical for a new position

Finanznachrichten News

Veronica Wallin, Episurf Medical's CFO since June 2017 and previously Head of Finance since August 2016, has today announced her resignation from Episurf for a new opportunity.

"It's almost 9 years since I started at Episurf, and I'm extremely proud of everything we've achieved together. Episurf has a continued exciting journey ahead but now is a good time for me to take on a new challenge. I will ensure a good handover to the next CFO and continue to follow the company from a distance", says Veronica Wallin, outgoing CFO of Episurf Medical.

"Veronica is a highly valued and competent colleague who has been a key person to us. She has been part of Episurf's journey and contributed to the company being where we are today. I completely understand and respect her decision to, after 9 years, try her wings elsewhere, and I wish her all the best in the future," says Pål Ryfors, CEO of Episurf Medical.

Veronica Wallin will leave Episurf during the second quarter 2025. A recruitment process for a new CFO has been initiated.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 16.35 CET on 18 March 2025.


© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.